Drug Evaluation: Oncologic, Endocrine & Metabolic: Irinotecan (CPT-11): Current status and perspectives
- 1 June 1996
- journal article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 5 (6), 613-626
- https://doi.org/10.1517/13543784.5.6.613
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Inhibition of cis‐diamminedichloroplatinum (II)‐induced DNA interstrand cross‐link removal by 7‐ethyl‐10‐hydroxy‐camptothecin in HST‐1 human squamous‐carcinoma cellsInternational Journal of Cancer, 1995
- Determinants of drug response in camptothecin-11-resistant glioma cell linesJournal of Neuro-Oncology, 1995
- Effects of CPT‐11 (a unique DNA topoisomerase I inhibitor) on a highly malignant xeno‐transplanted neuroblastomaMedical and Pediatric Oncology, 1994
- Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: Characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11Journal of Surgical Oncology, 1993
- Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell lineBiochemical and Biophysical Research Communications, 1992
- Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cellsEuropean Journal Of Cancer, 1992
- Effects of CPT‐11 in combination with other anti‐cancer agents in cultureInternational Journal of Cancer, 1992
- Synthesis and Antitumor Activity of 20(S)-Camptothecin Derivatives: A-Ring Modified and 7,10-Disubstituted Camptothecins.CHEMICAL & PHARMACEUTICAL BULLETIN, 1991
- Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cellsEuropean Journal of Cancer and Clinical Oncology, 1990
- Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2Journal of the American Chemical Society, 1966